BIO logo

BIO
Bio-Rad Laboratories Inc. - Ordinary Shares - Class A

1,008
Mkt Cap
$8.16B
Volume
261,853.00
52W High
$343.12
52W Low
$211.43
PE Ratio
50.26
BIO Fundamentals
Price
$317.13
Prev Close
$305.29
Open
$307.40
50D MA
$275.63
Beta
0.93
Avg. Volume
274,215.21
EPS (Annual)
$27.85
P/B
1.20
Rev/Employee
$346,738.26
$8,108.47
Loading...
Loading...
News
all
press releases
Why Elliott Sees Hidden Billions Inside Bio-Rad Laboratories
Elliott Management builds a stake in Bio-Rad (NYSE: BIO) to push for better performance, but family voting control could pose a hurdle.read more...
News Placeholder
More News
News Placeholder
Bio-Rad to Participate in Upcoming Investor Conferences
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced that the company will participate in the following...
News Placeholder
Bio-Rad Laboratories (NYSE:BIO.B) Trading Down 12.8% - Time to Sell?
Bio-Rad Laboratories (NYSE:BIO.B) Trading Down 12.8% - Here's Why...
News Placeholder
Bio-Rad Laboratories (NYSE:BIO.B) Shares Gap Down - Should You Sell?
Bio-Rad Laboratories (NYSE:BIO.B) Shares Gap Down - Here's What Happened...
News Placeholder
Bio-Rad Laboratories, Inc. (NYSE:BIO) Receives Average Rating of "Hold" from Analysts
Shares of Bio-Rad Laboratories, Inc. (NYSE:BIO - Get Free Report) have earned an average rating of "Hold" from the five brokerages that are presently covering the stock, MarketBeat.com reports. One research analyst has rated the stock with a sell recommendation, three have given a hold recommendat...
News Placeholder
Unlocking Bio-Rad (BIO) International Revenues: Trends, Surprises, and Prospects
Explore how Bio-Rad's (BIO) revenue from international markets is changing and the resulting impact on Wall Street's predictions and the stock's prospects.
News Placeholder
Wells Fargo & Company Has Lowered Expectations for Bio-Rad Laboratories (NYSE:BIO) Stock Price
Wells Fargo & Company decreased their target price on Bio-Rad Laboratories from $320.00 to $290.00 and set an "equal weight" rating for the company in a research note on Friday...
News Placeholder
Bio-Rad Laboratories (NYSE:BIO) Shares Gap Down Following Weak Earnings
Bio-Rad Laboratories (NYSE:BIO) Shares Gap Down After Earnings Miss...
News Placeholder
Bio-Rad Laboratories Q1 Earnings Call Highlights
Bio-Rad Laboratories (NYSE:BIO) reported first-quarter 2026 results that fell within its revenue guidance range, while management emphasized that geopolitical disruption in the Middle East and continued weakness in academic research demand are weighing on growth and profitability expectations for th...
News Placeholder
Bio-Rad Laboratories (NYSE:BIO) Announces Earnings Results
Bio-Rad Laboratories (NYSE:BIO - Get Free Report) announced its quarterly earnings data on Thursday. The medical research company reported $1.89 earnings per share for the quarter, missing analysts' consensus estimates of $1.97 by ($0.08). The business had revenue of $592.10 million during the...
<
1
2
...
>

Compact View

Mini-Chart
Sentiment
Not available
Message Volume
Not available